Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate

Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Clin Oncol
Prif Awduron: Yasui, Masato, Hasegawa, Yoriko, Kawahara, Takashi, Kumano, Yohei, Miyoshi, Yasuhide, Matsubara, Nobuaki, Uemura, Hiroji
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: D.A. Spandidos 2018
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838297/
https://ncbi.nlm.nih.gov/pubmed/29541468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1573
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg